Systemic Aspergillosis And Systemic Candidiasis Market Report 2026

Systemic Aspergillosis And Systemic Candidiasis Market Overview

• Systemic Aspergillosis And Systemic Candidiasis market size has reached to $7.57 billion in 2025 • Expected to grow to $9.76 billion in 2030 at a compound annual growth rate (CAGR) of 5.3% • Growth Driver: Rising Incidence Of Fungal Diseases Spurs Growth In The Systemic Aspergillosis And Systemic Candidiasis Market • Market Trend: Advancements In Echinocandins For Systemic Fungal Infection In The Systemic Aspergillosis And Systemic Candidiasis Markets • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Systemic Aspergillosis And Systemic Candidiasis Market?

Systemic aspergillosis is the most lethal type of aspergillosis, which develops when the infection spreads to other organs besides the lungs, and systemic candidiasis refers to a range of yeast infections brought on by different species of Candida. Systemic aspergillosis and systemic candidiasis are severe illnesses that can harm the blood, heart, brain, eyes, bones, or other body organs. The main types of systemic aspergillosis and systemic candidiasis are systemic oral azoles, voriconazole, liposomal amphotericin B, topical antifungal agents, and others. Systemic oral azoles refer to a group of antifungal drugs ingested to fight systemic fungal infections throughout the body that act by concentrating on particular enzymes necessary for fungi to survive, they prevent the growth and replication of fungal cells. They are used for allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), gastrointestinal candidiasis, genitourinary tract candidiasis, and others by clinics, hospitals, and others.

What Is The Systemic Aspergillosis And Systemic Candidiasis Market Growth Forecast?

The systemic aspergillosis and systemic candidiasis market size is expected to see strong growth in the next few years. It will grow to $9.76 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing development of novel antifungal agents, rising focus on antifungal resistance management, expansion of targeted antifungal therapies, growing investments in infectious disease research, increasing adoption of combination treatment regimens. Major trends in the forecast period include increasing adoption of advanced antifungal therapies, rising focus on early diagnosis of systemic fungal infections, expansion of combination antifungal treatment approaches, growing demand for hospital-based critical care antifungals, enhanced monitoring of drug resistance patterns.

Global Systemic Aspergillosis And Systemic Candidiasis Market Segmentation

1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types 2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications 3) By End User: Clinic, Hospital, Other End Users Subsegments: 1) By Systemic Oral Azoles: Fluconazole, Itraconazole, Posaconazole, Voriconazole 2) By Voriconazole: Voriconazole Tablets, Voriconazole Injection 3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis, Liposomal Amphotericin B For Systemic Candidiasis 4) By Topical Antifungal Agents: Topical Azoles, Topical Polyenes, Topical Allylamines 5) By Other Types: Echinocandins, Antifungal Combination Therapies, Other Emerging Antifungal Agents

What Is The Driver Of The Systemic Aspergillosis And Systemic Candidiasis Market?

The increase in the incidence of fungal diseases is expected to propel the growth of the systemic aspergillosis and systemic candidiasis market going forward. Fungal diseases refer to infections caused by fungi that can affect various body parts, resulting in multiple symptoms and complications. These diseases include cutaneous skin infections, respiratory infections, and systemic infections. Fungal diseases are treated with antifungal medications such as oral azoles, voriconazole, and liposomal amphotericin B. For instance, in 2023, according to the Uk Health Security Agency, a UK-based government agency, in 2023, the rate of yeast-related bloodstream infections across England rose by 4% compared to 2022. Therefore, the increase in the incidence of fungal disease is driving the growth of the systemic aspergillosis and systemic candidiasis industry.

Key Players In The Global Systemic Aspergillosis And Systemic Candidiasis Market

Major companies operating in the systemic aspergillosis and systemic candidiasis market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A, GlaxoSmithKline PLC, Gilead Sciences Inc, Astellas Pharma Inc, Matinas BioPharma Holdings Inc, Shionogi & Co. Ltd, Cipla Limited, Basilea Pharmaceutica Ltd, Cidara Therapeutics Inc, Entasis Therapeutics Inc, F2G Ltd, Mycovia Pharmaceuticals Inc, ContraFect Corporation, Enzon Pharmaceutical Inc, Pacgen Life Science Corporation, Biosergen AS

Global Systemic Aspergillosis And Systemic Candidiasis Market Trends and Insights

Major companies operating in the systemic aspergillosis and systemic candidiasis markets are concentrating on the development of advanced products, such as echinocandins, to enhance treatment efficacy and address the growing challenges of antifungal resistance. Echinocandins are a class of antifungal drugs that inhibit the synthesis of β-glucan, an essential component of the fungal cell wall. For instance, in March 2023, Cidara Therapeutics, a US-based biotechnology company, and Melinta Therapeutics, a US-based biotechnology company, received approval from the Food and Drug Administration (FDA), a US-based federal agency for protecting public health for REZZAYO (rezafungin for injection). REZZAYO (rezafungin for injection) is a novel once-weekly echinocandin for the treatment of candidemia in adults who have limited or no alternative treatment options. Designed for ease of administration, REZZAYO's once-weekly dosing regimen simplifies treatment and enhances the continuity of care for patients with invasive candidiasis. It is particularly beneficial for those in hospital settings, where effective management of such infections is critical.

What Are Latest Mergers And Acquisitions In The Systemic Aspergillosis And Systemic Candidiasis Market?

In August 2023, Sandoz, a Germany-based global pharmaceutical company, acquired Astellas Pharma Inc. for an undisclosed amount. With this acquisition, Sandoz aims to significantly enhance its hospital offerings and expand its anti-infectives portfolio, enabling the company to provide critical antimicrobial medicines and support responsible use through targeted therapies for patients in need. Astellas Pharma Inc. is a Japan-based global pharmaceutical company that provides treatment for systemic aspergillosis and systemic candidiasis.

Regional Outlook

North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Systemic Aspergillosis And Systemic Candidiasis Market?

The systemic aspergillosis and systemic candidiasis market consists of sales of voriconazole and amphotericin B. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Systemic Aspergillosis And Systemic Candidiasis Market Report 2026?

The systemic aspergillosis and systemic candidiasis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the systemic aspergillosis and systemic candidiasis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.